India’s Disproportionate Use of ‘Watch’ Antibiotics Signals a Growing Public Health Dilemma

NEW DELHI — India is facing a complex public health challenge driven by the widespread consumption of powerful “watch” antibiotics—medications intended to be reserved for specific, severe bacterial infections. According to a landmark study published in The Lancet Public Health, the country’s current antibiotic consumption relies heavily on broad-spectrum agents, leaving safer first-line treatments underutilized while failing to supply critical last-resort drugs to those who need them most.

The global analysis, led by researchers at City St. George’s, University of London, in collaboration with international health experts, underscores a structural crisis in South Asia: an overlap of overconsumption in urban private care alongside acute access barriers in resource-strapped public clinics. As bacterial pathogens adapt, public health agencies warn that unchecked misuse could accelerate antimicrobial resistance (AMR), transforming routinely treatable conditions into dangerous medical threats.

What the Research Reveals: The Disparity in Prescribing

The World Health Organization (WHO) categorizes antibiotics into three primary groups under its AWaRe framework to preserve their global effectiveness:

• Access: Narrow-spectrum, first-line antibiotics (such as amoxicillin) that effectively treat common infections while posing a lower risk of driving resistance.

• Watch: Broad-spectrum medications (such as third-generation cephalosporins and fluoroquinolones) that should be prescribed cautiously due to their high potential for generating resistant bacterial strains.

• Reserve: Last-resort antibiotics (such as colistin or linezolid) strictly intended for severe, multi-drug resistant infections.

United Nations guidelines recommend that at least 70% of a country’s antibiotic consumption should consist of “Access” group medicines. However, The Lancet Public Health study revealed that only 27% of antibiotic use in India comes from the Access category. In contrast, “Watch” category antibiotics account for the largest share of clinical consumption.

Standard Target vs. Actual Antibiotic Usage in India

Target (WHO/UN)  [████████████████████████████████████████ 70%+ Access ]
India Actual     [███████████ 27% Access ] [██████████████████ Watch/Other ]

The study estimated India’s baseline medical requirement at 14.7 Defined Daily Doses (DID) per 1,000 people per day. Actual consumption stands at 18.3 DID. While “Watch” category usage reaches 9.3 DID—well above the estimated clinical need of 6.0 DID—use of “Reserve” drugs remains strikingly low at 0.19 DID, despite high estimated demand (0.99 DID).

This builds upon earlier research, including a 2021 study in The Lancet Planetary Health, which found that unapproved fixed-dose combinations (FDCs)—formulations pairing two or more drugs into a single pill—accounted for a massive fraction of systemic antibiotic sales in India. Furthermore, separate global burden analyses published in The Lancet indicated that in 2019, only 7.8% of carbapenem-resistant infections in India received appropriate targeted therapy, highlighting a severe treatment gap for critically ill patients.

The Broader Impact of Antimicrobial Resistance

Antimicrobial resistance occurs when bacteria adapt over time, making standard antibiotic therapies ineffective. When broad-spectrum “Watch” drugs are used routinely for mild or viral ailments, susceptible bacteria are eradicated while resistant strains survive and multiply.

Globally, bacterial AMR was directly responsible for an estimated 1.27 million deaths in 2019 and played a role in nearly 5 million total fatalities. South Asia remains one of the hardest-hit regions.

When first-line treatments fail:

• Routine surgical procedures, chemotherapy, and organ transplants become significantly higher risk due to post-operative infection threats.

• Hospital stays are prolonged, increasing medical expenditure for families and placing additional burden on healthcare infrastructure.

• Patient mortality rates rise sharply as clinicians run out of effective therapeutic options.

Expert Perspectives: A System-Wide Challenge

Medical experts emphasize that the issue extends beyond individual clinical decisions.

“Our study found that in India, some patients were exposed unnecessarily to antibiotics while others did not have access to the right antibiotics to treat their infections,” said Prof. Ramanan Laxminarayan, founder and president of the One Health Trust and senior research scholar at Princeton University, who co-authored the Lancet report.

Public health analysts point to a combination of systemic drivers:

1. Self-Medication and OTC Sales: Despite regulatory Schedule H1 mandates restricting direct sales, over-the-counter dispensing of broad-spectrum antibiotics without a valid prescription remains prevalent.

2. Diagnostic Delays: In primary care settings, rapid diagnostic tools are often unavailable. Doctors frequently prescribe broad-spectrum “Watch” antibiotics empirically to protect against potential bacterial complications, rather than waiting days for culture results.

3. Patient Expectations: Patients often request fast-acting relief for winter colds, seasonal influenza, or mild diarrheal illnesses. Because antibiotics do not treat viral infections, this practice exposes individuals to unnecessary drug side effects while contributing to microbial resistance.

Actionable Guidance for Patients

Healthcare institutions emphasize that individual action plays an important role in preserving antibiotic efficacy.

• Avoid Self-Medication: Never purchase antibiotics over the counter without a direct, formal prescription from a qualified physician.

• Understand the Infection Type: Colds, flu, and most sore throats are viral. Ask your healthcare provider if an antibiotic is genuinely necessary or if symptomatic care is more appropriate.

• Follow Prescriptions Precisely: Take the medication exactly as instructed. Stopping early—even if symptoms resolve—allows surviving, partially resistant bacteria to replicate.

• Never Share or Reuse Medication: Do not save leftover antibiotics for future illnesses or share them with family members. Treatments are specific to the individual, the pathogen, and the dosage required.

Study Limitations and Clinical Nuance

While national consumption data provides clear direction, researchers acknowledge inherent limitations. Sales database metrics may overlook informal distribution channels in rural areas, potentially undercounting total volume while overestimating access to regulated supplies. Additionally, modeling baseline clinical requirements relies on population-wide estimates of disease burden, which can vary significantly across states.

Experts stress that reducing antibiotic overuse must not lead to withholding necessary treatments. In acute bacterial sepsis or severe pneumonia, delaying broad-spectrum therapy can be fatal. The primary goal of antimicrobial stewardship is not restricting care, but ensuring the right drug is given at the right dose, for the right duration.

References

1. https://indianexpress.com/article/health-wellness/antibiotics-india-medicines-infections-global-lancet-study-10797590/

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.